DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for endometrial carcinoma — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEndometrial carcinoma maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for endometrial carcinoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
dihydrofolate reductase (DHFR) — DHFR is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet ndpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 4M6J · 1.201 Å · ligand NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE (NDP). Experimental structure, not a prediction.
What the evidence adds up to
A 2014 expert consensus document on advanced stage endometrial carcinoma notes that patients form a heterogeneous group with different stages, histologic types and sites of involvement. Hysterectomy, bilateral salpingo-oophorectomy and surgical staging remain the cornerstone of surgical management. The document states that the optimal adjuvant therapy is not yet established, and that where evidence is lacking or not definitive, expert opinion is used to recommend imaging or treatment. Four clinical variants were developed to cover common scenarios, and the panel reached consensus on numerical ratings for specific evaluation and treatment approaches.
A 2006 review describes endometrial cancer as the most common malignancy of the female genital tract in the United States. It reports that molecular studies have provided a genetic basis for a broad classification of the disease, and that a mouse model has been developed to study the interaction of genetic alterations and hormones in the pathogenesis of endometrioid carcinoma. A 2012 review on angiogenesis in endometrial carcinoma states that angiogenesis is closely related to the occurrence, development, invasion and metastasis of the disease, and that it is a complex process involving many factors.
No clinical trial data for any drug—whether repurposed or not—are reported in these abstracts. No response rates, survival figures, or sample sizes are given. The 2014 document explicitly says the optimal adjuvant therapy is not yet established.
What is still missing are randomised controlled trials that test specific drug regimens, including repurposed agents, in defined subgroups of advanced endometrial carcinoma. Patient stratification by histologic type, molecular subtype, and prior treatment is needed. Funding for such trials, and for the biomarker development that would enable stratification, remains absent from these summaries.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Clinical Oncology · 2014 · 12 citations
ACR Appropriateness Criteria® Advanced Stage Endometrial Cancer
AbstractOBJECTIVES: Patients with advanced stage endometrial carcinoma constitute a heterogeneous group of patients with different stages, tumor histologic types, and involved sites. Hysterectomy, bilateral salpingo-ophorectomy, and surgical staging are the cornerstone of surgical management in these patients. The optimal adjuvant therapy is yet to be established. An expert panel was convened to reach consensus on the most appropriate management options in this group of patients. METHODS: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 3 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment. RESULTS: Four clinical variants were developed to address common scenarios in the management of women with advanced-stage endometrial carcinoma. Group members reached consensus on the appropriateness of specific evaluation and treatment approaches with numerical ratings. CONCLUSIONS: In combining available medical literature and expert opinions, this manuscript may serve as an aid for other practitioners in the appropriate management of women with advanced-stage endometrial carcinoma.
Encyclopedia of Life Sciences · 2006 · 0 citations
Endometrial Cancer
AbstractAbstract Endometrial cancer is the most common malignancy of the female genital tract in the United States. Molecular studies have led to key insights into the pathogenesis of endometrial carcinoma and have provided a genetic basis for the current broad classification of this common malignancy. The recent development of a mouse model will promote studies aimed at understanding the interaction of genetic alterations and hormones in the pathogenesis of endometrioid carcinoma.
Progress of the angiogenesis correlation factors for endometrial carcinoma
AbstractAngiogenesis is closely related to the occurrence,development,invasion and metastasis of endometrial carcinoma.In recent years,a large number of researches on the angiogenesis correlation factors for endometrial carcinoma have been carried out It is shown that endometrial carcinoma angiogenesis is a complex process with many factors involved in.
Key words:
Endometrial neoplasms; Vascular endothelial growth factors; Angiogenesis inhibitors
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
